secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001641172-25-013466
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric stockholders approve conditional reverse stock split to avoid Nasdaq delisting
--------------------------------------------------------------------------------

- Stockholders authorized board to implement reverse stock split between 1:5 and 1:50 if Nasdaq issues bid price delisting determination before Jan 28, 2026.
- Reverse stock split proposal passed with 881,471 votes for, 301,346 against, 23,681 abstentions.
- All six director nominees elected; Michael D. Webb received 175,763 votes for, 155,118 withheld (875,617 broker non-votes).
- Say-on-pay proposal passed with 253,560 votes for, 75,850 against, 1,471 abstentions.
- Auditor ratification of CBIZ CPAs P.C. passed with 1,082,606 votes for, 115,857 against, 8,035 abstentions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000164117225013466/0001641172-25-013466-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000164117225013466/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-013466

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer